Amazon falls 7%, Intel plunges 25% in premarket trading, as pressure mounts after earnings
Amazon missed third-quarter revenue and earnings expectations, and its fourth-quarter outlook was light. [[fact-g9rs3mh9w]] AWS grew 39% in the third quarter, its fastest pace in nearly five years. [[fact-dg25a0g6f]] Online store sales fell short of expectations. [[fact-zwbyhdhtp]] Overall sales grew 12% to $201.9 billion. [[fact-emf6cp7yd]] Operating income rose 61% to $28.1 billion, while operating margin increased to 13.9% from 9.7% a year earlier. [[fact-ee8s4htb7]] Third-quarter capital expenditures exceeded Wall Street expectations, contributing to an overnight stock decline of more than 7%. [[fact-m04987rdz]]
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs - Zacks Investment Research
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs - Zacks Investment Research(摘要待生成)
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - Yahoo Finance(摘要待生成)
Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus - Yahoo Finance
Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus - Yahoo Finance(摘要待生成)
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery - Yahoo Finance
Iovance reported Q3 2026 revenue of US$121.5 million, up from US$67.5 million a year earlier. [[fact-aofwmt32a]] Its Q3 net loss was US$22.3 million, compared with US$91.3 million a year earlier. [[fact-908q1had6]] Gross margin rose to roughly 60% in Q3 2026 from roughly 56% in Q2 2026. [[fact-eadqqod7d]] The company reiterated 2026 revenue guidance of US$410 million to US$420 million. [[fact-nor463l2t]]
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ... - Yahoo Finance
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ... - Yahoo Finance(摘要待生成)
Iovance Biotherapeutics Q3 Earnings Call Highlights - Yahoo Finance
Iovance Biotherapeutics Q3 Earnings Call Highlights - Yahoo Finance(摘要待生成)
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow (NASDAQ:IOVA) 2026-10-29 - Seeking Alpha
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow (NASDAQ:IOVA) 2026-10-29 Seeking Alpha
IOVA Stock Collapses As Traders Flee Biotech High‑Flier - StocksToTrade
IOVA Stock Collapses As Traders Flee Biotech High‑Flier - StocksToTrade(摘要待生成)
IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?
IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall? Stocktwits
Iovance Biotherapeutics (IOVA) Reports Promising Phase 2 Trial R - GuruFocus
Iovance Biotherapeutics (IOVA) Reports Promising Phase 2 Trial R GuruFocus
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results(摘要待生成)
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Iovance Biotherapeutics announced a conference call and live audio webcast for October 29, 2026, to present positive results from the IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous mNSCLC.
Iovance Biotherapeutics Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for mNSCLC
Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial for lifileucel in non-small cell lung cancer and introduced a new biomarker-enriched precision TIL strategy.
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast on November 5, 2026, to discuss its third quarter 2026 financial results and provide corporate updates.